Portfolio company
Step Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
5 investors
Sectors
About
This company develops selective CTPS1 inhibitors to treat patients with blood cancers, solid tumours and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
TwoStep Therapeutics
The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.
CasInvent
This company develops selective casein kinase 1 inhibitors to treat resistant cancers, including leukaemias and solid tumours, for patients with limited treatment options.
DualTPharma
This company develops bacteria-based drug delivery systems to transport immunotherapies into solid tumours for cancer patients.
Clasp Therapeutics
This company develops T cell engagers that target oncogenic driver mutations to treat patients with solid tumours.
Type6 Therapeutics
This deep-tech company develops kinase inhibitors for cancer treatment, intercepting enzymes in their inactive states to address drug resistance for patients with aggressive tumours.
Athernal Bio
The company develops targeted immunotherapies for patients with high-risk clonal haematopoiesis to prevent the development of blood cancers.
BRENUS PHARMA
This company develops allogeneic cancer immunotherapies for patients with solid tumors using a proteomics-guided platform that mimics tumor cell resistance and escape mechanisms.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.